Clinical Implications and Policy Recommendations for Incorporating Fructosamine in Diabetes Care
IFR Journal of Medical Science and Case Report · 09.10.2025 · 1 (4) · 10-16
DOI: 10.70146/mscrv01i04.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift IFR Journal of Medical Science and Case Report, erschienen am 09.10.2025. Verfasst von Anjani Kumar Chaturvedi und 1 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Diabetes mellitus requires effective glycemic control to reduce the risk of complications such as nephropathy, retinopathy, and neuropathy. Hemoglobin A1c (HbA1c) is commonly used to assess long-term glycemic control; however, its accuracy is compromised in patients with comorbidities such as anemia, hemoglobinopathies, and chronic kidney disease (CKD). Fructosamine, a marker reflecting short-term glycemic control over 2–3 weeks, is suggested as a complementary biomarker to HbA1c. This study explores the clinical implications and policy recommendations for incorporating fructosamine into routine diabetes care.
Objective
To evaluate the diagnostic accuracy, cost-effectiveness, and feasibility of fructosamine as a complementary biomarker to HbA1c in diabetic patients with anemia, hemoglobinopathies, and CKD, and to provide policy recommendations for its inclusion in clinical practice.
Methods
This prospective observational study included 1,200 diabetic patients (400 with anemia, 400 with hemoglobinopathies, and 400 with CKD). Participants were monitored over a 12-month period, with HbA1c and fructosamine levels measured at baseline, six months, and 12 months. Sensitivity, specificity, and correlation between the biomarkers were evaluated. A cost-effectiveness analysis was conducted to compare the cost of fructosamine and HbA1c testing in resource-limited settings.
Results
Fructosamine showed superior sensitivity and specificity compared to HbA1c, particularly in patients with anemia, hemoglobinopathies, and CKD. Fructosamine demonstrated higher sensitivity in detecting glycemic control shifts (92% in anemia, 90% in hemoglobinopathies, 89% in CKD) compared to HbA1c (75%, 78%, and 77%, respectively). Fructosamine testing was also more cost-effective, with a cost-saving of approximately 57% compared to HbA1c. Additionally, fructosamine testing was more accessible in resource-limited settings, with 90% of clinics offering it compared to 60% for HbA1c.
Conclusion
Fructosamine is a reliable and cost-effective alternative to HbA1c for monitoring glycemic control, especially in populations with comorbidities affecting HbA1c reliability. Its integration into routine diabetes care could improve management, particularly in resource-limited settings. Further research and policy development are necessary to expand its use in clinical practice.
Zitieren
APA
Chaturvedi, A. K., & Nigoskar, S. (2025). Clinical Implications and Policy Recommendations for Incorporating Fructosamine in Diabetes Care. IFR Journal of Medical Science and Case Report, 1(4), 10-16. https://doi.org/10.70146/mscrv01i04.002
Vancouver
Chaturvedi AK, Nigoskar S. Clinical Implications and Policy Recommendations for Incorporating Fructosamine in Diabetes Care. IFR Journal of Medical Science and Case Report. 2025;1(4):10-16. doi:10.70146/mscrv01i04.002
BibTeX
@article{Chaturvedi2025,
author = {Chaturvedi, Anjani Kumar and Nigoskar, Shreya},
title = {Clinical Implications and Policy Recommendations for Incorporating Fructosamine in Diabetes Care},
journal = {IFR Journal of Medical Science and Case Report},
year = {2025},
volume = {1},
number = {4},
pages = {10--16},
doi = {10.70146/mscrv01i04.002}
}
EUVIMED